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Behavioral/Systems/Cognitive
Glucocorticoid Effects on Memory Consolidation Depend on
Functional Interactions between the Medial Prefrontal
Cortex and Basolateral Amygdala
Benno Roozendaal,1 Jayme R. McReynolds,2 Eddy A. Van der Zee,3 Sangkwan Lee,4 James L. McGaugh,4
and Christa K. McIntyre2
1Department of Neuroscience, Section Anatomy, University Medical Center Groningen, University of Groningen, 9713 AV Groningen, The Netherlands,
2School of Behavioral and Brain Sciences, University of Texas, Dallas, Dallas, Texas 75083, 3Department of Molecular Neurobiology, University of
Groningen, 9750 AA Haren, The Netherlands, and 4Center for the Neurobiology of Learning and Memory, Department of Neurobiology and Behavior,
University of California, Irvine, Irvine, California 92697-3800
Considerable evidence indicates that the basolateral complex of the amygdala (BLA) interacts with efferent brain regions in mediating
glucocorticoid effects on memory consolidation. Here, we investigated whether glucocorticoid influences on the consolidation of mem-
ory for emotionally arousing training depend on functional interactions between the BLA and the medial prefrontal cortex (mPFC), a
brain region involved in higher-order cognitive and affective processing. The glucocorticoid receptor (GR) agonist 11,17-dihydroxy-
6,21-dimethyl-17-pregna-4,6-trien-20yn-3-one (RU 28362) administered unilaterally into the left mPFC of male Sprague Dawley rats
immediately after inhibitory avoidance training enhanced 48 h retention performance. An ipsilateral, but not contralateral, lesion of the
BLA blocked the memory enhancement. In a second experiment, RU 28362 infused into the mPFC after inhibitory avoidance training
increased BLA levels of phosphorylated extracellular signal-regulated kinase 1/2 (pErk1/2). Blockade of this pErk1/2 activity in the
BLA with the mitogen-activated protein kinase kinase inhibitor PD98059 [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-
one] prevented the memory enhancement, suggesting that GR agonist administration into the mPFC enhances memory consoli-
dation viamodulation of BLA activity. Conversely, GR agonist infusions administered into the BLA posttraining increased pErk1/2
levels in the mPFC in regulating memory consolidation. Moreover, as assessed with a two-phase inhibitory avoidance procedure
designed to separatemodulatory influences onmemory of context and footshock, posttraining GR agonist infusions into either the
BLA or mPFC enhanced memory of the contextual as well as aversive information acquired during inhibitory avoidance training.
These findings indicate that glucocorticoid effects onmemory consolidation depend on bidirectional interactions between the BLA
and mPFC.
Introduction
It is well established that glucocorticoid hormones, released from
the adrenal cortex in response to stressful stimuli, strengthen the
consolidation of long-term memories of emotionally arousing
experiences (de Kloet et al., 1999; Roozendaal, 2000; McGaugh
and Roozendaal, 2002; Sandi and Pinelo-Nava, 2007). The baso-
lateral complex of the amygdala (BLA), which has a moderate
density of glucocorticoid receptors (GRs), is crucially involved in
mediating glucocorticoid effects onmemory consolidation. AGR
agonist infused into the BLA after training enhances memory
consolidation (Roozendaal andMcGaugh, 1997b; Roozendaal et
al., 2002), whereas lesions or temporary inactivation of the BLA
block the memory-enhancing effect of systemically administered
glucocorticoids (Roozendaal andMcGaugh, 1996; Roozendaal et
al., 1996; Quirarte et al., 1997). Glucocorticoid-induced amyg-
dala activation is known to enhance memories of emotionally
arousing training experiences via efferent projections that acti-
vate many other brain regions, including the hippocampus, dor-
sal striatum, and neocortical regions (Roozendaal andMcGaugh,
1997a; Dolcos et al., 2004; McIntyre et al., 2005; Huff et al., 2006;
Tsoory et al., 2008).
A growing body of evidence indicates that BLA neuronal ac-
tivity is closely regulated by themedial prefrontal cortex (mPFC),
a brain region involved in higher-order cognitive and affective
processing as well as executive function (Davidson, 2002; Quirk
and Gehlert, 2003). The evidence suggests that there are recipro-
cal connections between the mPFC and BLA (Pe´rez-Jaranay and
Vives, 1991; Rosenkranz and Grace, 2002; Likhtik et al., 2005)
that regulate affect and memory (Garcia et al., 1999; Milad and
Quirk, 2002; Laviolette et al., 2005; Laviolette and Grace, 2006).
Maintenance of mPFC activity is known to constrain BLA activ-
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ity, whereas stress and glucocorticoids alter mPFC functioning,
thereby increasing BLA responses to emotionally arousing stim-
uli (Lyons et al., 2000; Amat et al., 2005). Like the BLA, mPFC
functioning is known to influence the consolidation of memory
of emotionally arousing training (Runyan and Dash, 2004;
Akirav andMaroun, 2006; Izquierdo et al., 2007). However, pre-
vious studies have not investigated whether the mPFC and
BLA interact in regulating memory consolidation. Moreover,
previous experiments have not investigated whether the
mPFC is a locus of glucocorticoid action in regulatingmemory
consolidation.
To address these issues, a first experiment examined whether
the specific GR agonist 11,17-dihydroxy-6,21-dimethyl-17-
pregna-4,6-trien-20yn-3-one (RU 28362) administered into the
mPFC immediately after emotionally arousing inhibitory avoid-
ance training enhances memory consolidation and whether such
memory enhancement requires an intact BLA. The next experi-
ment investigated whether posttraining GR agonist infusions
into the mPFC increase BLA activity and whether such BLA acti-
vation is required for mediating the memory-modulatory effects
of intra-mPFC GR agonist administration. BLA activity was as-
sessed by determining phosphorylation levels of extracellular
signal-regulated kinase 1/2 (pErk1/2), a signaling cascade impli-
cated inmemory consolidation (Duvarci et al., 2005;Merino and
Maren, 2006). Because of the strong reciprocal interaction be-
tween these brain regions, the experiments also examined
whether the well known memory enhancement induced by GR
agonist infusions into the BLA depends on concurrent changes in
pErk1/2 activity levels within the mPFC. A final experiment in-
vestigated whether RU 28362 infused into either the mPFC or
BLA induces comparable effects on memory of the contextual
and aversive information acquired during inhibitory avoidance
training.
Materials andMethods
Subjects. Adult male Sprague Dawley rats (270–320 g at time of surgery)
from Charles River Breeding Laboratories were housed individually in a
temperature-controlled (22°C) vivarium room and maintained on a
standard 12 h light/dark cycle (7:00 A.M. to 7:00 P.M. lights on). Food
andwater were available ad libitum. Training and testingwere performed
during the light phase of the cycle between 10:00 A.M. and 3:00 P.M., at
the rat nadir of the circadian cycle for corticosterone. All experimental
procedures were in compliance with the National Institutes of Health
guidelines and were approved by the Institutional Animal Care and Use
Committee of the University of California, Irvine.
Surgery. Animals were adapted to the vivarium for at least 1 week
before surgery. They were anesthetized with sodium pentobarbital (50
mg/kg of body weight, i.p.), given atropine sulfate (0.4 mg/kg, i.p.) to
maintain respiration, and were subsequently injected with 3 ml of saline
to facilitate clearance of these drugs and prevent dehydration. The skull
was positioned in a stereotaxic frame (David Kopf Instruments), and
either unilateral (left hemisphere) or bilateral stainless-steel guide can-
nulae (23 gauge) were implanted with the cannula tips 1.5 mm above the
prelimbic region of the mPFC [11 mm; coordinates: anteroposterior
(AP),3.7 mm from bregma; mediolateral (ML),0.7 mm from mid-
line; dorsoventral (DV),2.4mm from skull surface] or 2mmabove the
BLA [15 mm; coordinates: AP,2.8 mm;ML,5.0 mm; DV,6.5 mm
(Paxinos and Watson, 2005)]. The cannulae were fixed to the skull with
two anchoring screws and dental cement. Stylets (11- or 15-mm-long
00-insect dissection pins) inserted into each cannula tomaintain patency
were removed only for drug infusions. Other groups of rats received a
unilateral neurotoxic lesion of either the ipsilateral or contralateral BLA
induced by NMDA (Sigma-Aldrich; 1.25 mg per 100 l of phosphate
buffer, pH 7.4) in addition to a unilateral cannula in the left mPFC. The
NMDA solution was backfilled into a 30 gauge needle, which was at-
tached by a polyethylene tube to a 10lHamiltonmicrosyringe driven by
a minipump (Sage Instruments). The needle tip was inserted into the
BLA (coordinates: AP, 2.8 mm; ML, 5.0 mm; DV, 8.6 mm), and
NMDA (2.5 g per 0.2 l of phosphate buffer) was infused over a 25 s
period. The injection needle was retained in place for an additional 3min
to optimize diffusion. Sham operations used the same procedure except
that the needle was lowered only to the level of the caudate/putamen
(coordinates: AP, 2.8 mm; ML, 5.0 mm; DV, 6.5 mm) and re-
moved after 3min without infusion. After surgery, the rats were retained
in an incubator until recovered from anesthesia and were then returned
to their home cages. Rats were allowed to recover from surgery for 7 d
before initiation of training.
Inhibitory avoidance apparatus and procedures. For all experiments, the
rats were trained in an inhibitory avoidance apparatus consisting of a
trough-shaped alley (91 cm long, 15 cm deep, 20 cm wide at the top, and
6.4 cmwide at the bottom) divided into two compartments, separated by
a sliding door that opened by retracting into the floor (McGaugh et al.,
1988). The starting compartment (31 cm) was made of opaque white
plastic and well lit; the shock compartment (60 cm) was made of dark,
electrifiable metal plates and was not illuminated. Training and testing
were conducted in a sound- and light-attenuated room.
For one-trial inhibitory avoidance training, the rats were placed in the
starting compartment of the apparatus, facing away from the door, and
were allowed to enter the dark (shock) compartment. After the rat
stepped completely into the dark compartment, the sliding door was
closed and a single inescapable footshock (0.35 mA; 1 s) was delivered.
The rats were removed from the shock compartment 15 s later and, after
drug treatment, returned to their home cages. For the modified, two-
phase inhibitory avoidance procedure (Malin and McGaugh, 2006), on
the first day (context training), the rat was placed into the starting com-
partment and allowed to freely explore the inhibitory avoidance appara-
tus for 3min.On day 2 (shock training), each rat was placed into the dark
compartment, facing away from the starting compartment, with the re-
tractable door closed. The rat then received an inescapable footshock and
immediately afterward was removed from the training apparatus. Rats of
themPFC experiment received a footshock intensity of 0.7mA for 1 s. As
the vehicle contained 1% ethanol, which is slightly impairing when in-
fused into the BLA, the BLA-cannulated rats received a somewhat higher
footshock intensity of 1.0 mA for 2 s to ensure memory in all experimen-
tal groups. For both one-trial and two-phase inhibitory avoidance, reten-
tion was tested 48 h after training by placing the rat into the starting
compartment of the inhibitory avoidance apparatus and measuring the
latency to enter the former shock compartment with all four paws (max-
imum latency of 600 s). Longer latencies were interpreted as indicating
better retention. Shock was not administered on the retention test trial.
Drug treatment.The specific GR agonist RU 28362 (Roussel Uclaf) was
administered into either themPFC (3 or 10 ng in 0.5l) or BLA (1 or 3 ng
in 0.2 l). Receptor binding studies have shown that this compound has
selective and high affinity for GRs (Teutsch et al., 1981). RU 28362 was
first dissolved in 100%ethanol and subsequently diluted in 0.9% saline to
reach a final ethanol concentration of 1%. Bilateral infusions of RU
28362 or an equivalent volume of vehicle (1% ethanol in saline) into
these brain regions were given immediately after inhibitory avoidance
training by using a 30 gauge injection needle connected to a 10 l Ham-
ilton microsyringe with polyethylene (PE-20) tubing. The use of post-
training drug administration provides direct support for the view that the
treatment affects memory consolidation processes and that the retention
performance is, thus, not confounded by possible effects on attentional,
motivational, or sensory-perceptual mechanisms at the time of training
or test (McGaugh, 1966). For mPFC infusions, the injection needle pro-
truded 1.5 mm beyond the tip of the cannula and a 0.5 l injection
volume was infused over a period of 35 s by an automated syringe pump
(Sage Instruments). For BLA infusions, the injection needle protruded
2.0mmbeyond the cannula tip and a 0.2l injection volumewas infused
during 25 s. The injection needles were retained within the cannulae for
an additional 20 s after drug infusion to maximize diffusion and to pre-
vent backflow of drug into the cannulae. For some experiments, the GR
agonist was administered unilaterally into either the mPFC or BLA to-
gether with the specific mitogen-activated protein kinase kinase (MEK)
14300 • J. Neurosci., November 11, 2009 • 29(45):14299–14308 Roozendaal et al. • Prefrontal–Amygdala Interactions in Memory
inhibitor 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
(PD98059) into the other brain region immediately after inhibitory
avoidance training. PD98059 acts by binding to the inactivated form of
MEK, thereby preventing its phosphorylation by MEK kinase. PD98059
(Tocris Bioscience) was first dissolved in 100%DMSO and subsequently
diluted in 0.9% saline to reach a final DMSO concentration of 6%. The
vehicle contained 6% DMSO in saline only. A total of 20 ng of PD98059
in 0.2 l was infused into the left BLA or 50 ng in 0.5 l into the left
mPFC, using procedures as described above. The infusion volume for the
BLA was based on extensive previous evidence that this volume of an
excitotoxin administered at an identical injection site induces selective
lesions of the BLA (Roozendaal and McGaugh, 1996, 1997a; current
data). Furthermore, drug infusions of this volume into the BLA, but not
into the adjacent central nucleus of the amygdala, modulate memory
consolidation (Roozendaal and McGaugh, 1997b; Roozendaal et al.,
2007; Campolongo et al., 2009). The infusion volume for the mPFC was
based on findings that infusions of this volume administered into the
rostral anterior cingulate cortex, located above the mPFC, produce dif-
ferent effects on the two-phase inhibitory avoidance task (Malin and
McGaugh, 2006).
Histology. The rats were deeply anesthetized with an overdose of so-
dium pentobarbital and perfused transcardially with 0.9% saline fol-
lowed by 4% formaldehyde solution (w/v). After decapitation, the brains
were removed and immersed in fresh 4% formaldehyde. At least 24 h
before sectioning, the brains were transferred to a 20% sucrose (w/v)
solution for cryoprotection. Coronal sections of 50 m were cut on a
freezing microtome, mounted on gelatin-coated slides, and stained with
cresyl violet. The sections were examined under a light microscope and
the location of injection needle tips in the mPFC and BLA or lesions of
the BLA were determined according to the standardized atlas plates of
Paxinos andWatson (2005) by an observer blind to drug treatment condi-
tion. For all experiments, only rats with needle tips within the boundaries of
themPFCor BLAwere included in the data analysis. Approximately 14%of
the animalswere excluded fromanalysis because of either cannulamisplace-
ment or damage to the targeted tissue.
Western blotting for p-Erk1/2 and mitogen-activated protein kinase. Fif-
teen minutes after training and immediate posttraining drug treatment,
rats were deeply anesthetized with sodium pentobarbital and brains were
rapidly removed and flash frozen by submersion for 2 min in a beaker of
2-methylbutane sitting in a dry ice–ethanol bath. Tissue punches (1 mm
in diameter) were taken from either the BLA or mPFC, bilaterally, with a
glass pipette. Tissue punches were sonicated in 0.1 M phosphate buffer,
pH 7.4 [containing 2% SDS, 10% glycerol, 20 M leupeptin, 0.1 mM
TLCK (N--p-tosyl-L-lysine chloromethyl ketone), NS 1 mM PMSF].
Protein concentrations were determined with a microplate reader and
Pierce protein assay kit. Approximately 15 g of protein from each sam-
ple was heated in sample buffer with reducing agent (Bio-Rad), loaded,
and run on 12% Tris-HCl gels (Bio-Rad). Samples from left and right
BLA ormPFC of an individual animal were loaded in adjacent wells. Gels
were then electroblotted to nitrocellulose membranes. Membranes were
treated as previously described (Sharma and Carew, 2002). Membranes
were first processed to detect phosphorylated p44/42 mitogen-activated
protein (MAP) kinase (pErk1/2) immunoreactivity and then stripped
and reprobed with antibody to total MAP kinase (1:1000 and 1:2000,
respectively; Cell Signaling Technology). Bio-Rad markers were run on
all gels to determine the relative mobility of the immunoreactive bands.
For quantification of immunoblot results, films were scanned and con-
verted into TIF files for analysis using Scion Image software. Phosphor-
ylated Erk1/2 immunoreactivity levels were normalized to the total MAP
kinase immunoreactivity value for each sample (Patterson et al., 2001;
Sharma et al., 2003).
Immunohistochemistry. Fifteen minutes after training and immediate
posttraining drug treatment, rats were deeply anesthetized with pento-
barbital and fixed by transcardial perfusion of 4% paraformaldehyde.
Brains were postfixed for 24 h at room temperature and then kept in 0.1 M
Tris-buffered saline (TBS) at 4°C. Twenty-five micrometer sections were
cut from the relevant brain area using a cryostat and transferred into TBS
with 0.2% Triton X-100. Free-floating sections were incubated for 2 h in
a blocking solution containing 10% of the appropriate normal serum in
TBS with phosphatase inhibitors (20 mM sodium fluoride and 2 mM
sodium orthovanadate), after which they were incubated overnight at
4°C with rabbit anti-phospho-p44/42 MAP kinase (pErk1/2) as primary
antibody overnight (1:1000; Cell Signaling). The sections were then in-
cubated for 2 h with biotinylated goat anti-rabbit IgG (1:400; Jackson
ImmunoResearch Laboratories) and visualized using ABC kits (Vector
Laboratories) according to the manufacturer’s instructions.
Statistics. Inhibitory avoidance training and retention latencies
were analyzed with one- or two-way ANOVAs. The source of the
detected significances was determined by Fisher’s post hoc tests. To
determine whether learning had occurred, paired t tests were used to
compare the training and retention latencies of the vehicle groups.
Western blot data were expressed as ratio of normalized pErk1/2
across hemispheres (ipsilateral to infusion/contralateral to infusion),
and ratios were compared across groups with one-way ANOVAs.
Data are expressed as mean  SEM. Values of p  0.05 were consid-
ered statistically significant. The number of rats per group is indicated
in the figure legends.
Results
Ipsilateral, but not contralateral, lesions of the BLA block
inhibitory avoidance retention enhancement induced by
posttraining intra-mPFC infusions of a GR agonist
This experiment examined whether immediate posttraining in-
fusions of a GR agonist administered into the mPFC would en-
hance 48 h retention performance of inhibitory avoidance
training and whether this retention enhancement depends on an
intact BLA. To address this issue, unilateral infusions of the GR
agonist RU 28362 (3 or 10 ng) or vehicle were administered into
the left mPFC immediately after inhibitory avoidance training to
rats with an NMDA-induced lesion of either the ipsilateral or
contralateral BLA.
Average step-through latencies for all groups during train-
ing (i.e., before footshock or drug treatment) were 12.6 0.6 s
(mean  SEM). In rats with lesions or sham lesions of the left
BLA, a two-way ANOVA for entrance latencies during training
showed no BLA lesion effect (F(1,62) 0.15; p 0.70). Also, rats
in different posttraining drug groups did not differ in their laten-
cies during training (F(2,62) 0.88; p 0.42). In rats with lesions
or sham lesions of the right BLA, there were also no significant
lesion (F(1,59)  0.04; p  0.84) or drug group effects (F(2,59) 
0.77; p 0.49) (data not shown).
Lesions of the ipsilateral BLA blocked thememory-enhancing
effect of posttraining intra-mPFC infusions of RU 28362. Figure
1A shows 48 h retention latencies of rats with sham- or NMDA-
induced lesions of the left BLA given posttraining infusions of RU
28362 into the left mPFC. Retention latencies of sham-lesioned
rats treated with vehicle were significantly longer than their en-
trance latencies during training (paired t test, p  0.001), indi-
catingmemory for the training experience. Two-wayANOVA for
retention latencies showed no significant RU 28362 effect (F(2,62)
1.78; p 0.17) but did show a significant lesion (F(1,62) 14.01;
p 0.0005) and interaction effect between both factors (F(2,62)
3.27; p  0.05). Additional analysis with Fisher’s post hoc tests
showed that, in sham-lesioned rats, posttraining infusions of the
higher dose of RU 28362 (10 ng) enhanced retention ( p 0.05,
compared with vehicle), whereas retention latencies of animals
given the lower dose (3 ng) approached, but failed to reach, sig-
nificance ( p 0.06). A lesion of the BLAmade ipsilaterally to the
mPFC infusion side alone did not affect retention ( p 0.71), but
blocked the retention-enhancing effect of RU 28362 infused into
the mPFC. Retention latencies of BLA-lesioned rats given either
dose of RU 28362 were significantly shorter than those of corre-
sponding sham-lesioned rats (both, p 0.05).
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In contrast, a lesion of the contralateral
BLA did not block the retention enhance-
ment induced by immediate posttraining
intra-mPFC administration of RU 28362
(Fig. 1B). Two-way ANOVA for 48 h re-
tention latencies showed a significant RU
28362 effect (F(2,59)  7.85; p  0.001),
but no lesion effect (F(1,59)  0.10; p 
0.75) or interaction effect between both
factors (F(2,59) 0.01; p 0.99). Admin-
istration of the higher dose of RU 28362
(10 ng) into the mPFC enhanced reten-
tion in both sham-lesioned ( p  0.05)
and BLA-lesioned rats ( p 0.01).
Cannula placement in the mPFC is
shown in Figure 1C. All injection needle
tips of rats included in the analysis were
localized in the prelimbic region of the
mPFC. A total of 10 rats with improper
cannula placement or extensive tissue
damage at the injection needle tip site was
excluded from additional analysis. Histo-
logical examination of the lesioned BLA
indicated that the lesioned area was char-
acterized by pyknosis and loss of neurons,
accompanied by extensive gliosis. In sev-
eral animals, the BLA lesion was not com-
plete, leaving most of the anterior part
intact, but typically 50% or more of the
nucleus was damaged. Thirteen rats with
improper lesions of either the ipsilateral
or contralateral BLA were excluded from
analysis. In some animals, whose data
were included in the analyses,minor dam-
age was seen in the cortex adjacent to the
BLA but the central nucleus of the amyg-
dala was intact in all animals. Figure 1D
shows the extent of minimum and maxi-
mum BLA lesions of rats included in the
experiment.
GR agonist infusions into the mPFC after inhibitory
avoidance training increase pErk1/2 levels in the BLA
As indicated above, manipulation ofmPFC activity can alter BLA
neuronal activity (Rosenkranz and Grace, 2002; Likhtik et al.,
2005). And, as the BLA is critically involved inmodulatingmem-
ory consolidation, it seems possible that manipulation of GR
activity in the mPFC after inhibitory avoidance training en-
hanced memory consolidation via influencing BLA activity. To
examine whether posttraining infusions of RU 28362 into the
mPFC modulate BLA activity, pErk1/2 levels in the BLA were
assessed in rats given vehicle or RU 28362 (3 or 10 ng in 0.5 l)
into the left mPFC immediately after inhibitory avoidance train-
ing. As the findings of the previous experiment indicate that the
GR agonist infused into the mPFC was only blocked by an ipsi-
lateral, and not contralateral BLA lesion, we compared pErk1/2
levels, normalized to total MAP kinase levels (Patterson et al.,
2001; Sharma et al., 2003), in the BLA of the stimulated side with
that of the nonstimulated control side. Figure 2A shows the ratio
of pErk1/2 expression in the BLA across the two hemispheres.
One-way ANOVA revealed a significant difference across groups
(F(2,24)  5.02; p  0.05). For rats given infusions of RU 28362
into the mPFC after inhibitory avoidance training, the ratio of
pErk1/2 protein levels in the BLA between the ipsilateral and
contralateral side was significantly greater than that seen in rats
receiving vehicle infusions (3 ng, p  0.05; 10 ng, p  0.01).
Importantly, pErk1/2 levels in the BLA did not increase after
infusions of RU28362 into themPFCof control rats thatwere not
trained on the inhibitory avoidance task (F(2,14) 1.59; p 0.24).
Figure 2B shows a representative example of an immunoblot
illustrating pErk1/2 and total MAP kinase levels in the ipsilateral
and contralateral BLA of the different experimental groups.
Some animals were processed for immunocytochemistry to
qualitatively confirm theWestern blot data and to determine the
location of increased pErk1/2 activitywithin theBLA.As is shown
in Figure 2C, posttraining infusions of RU 28362 (10 ng) into the
mPFC increased the density of pErk1/2-positive neurons scat-
tered throughout the BLA. The BLA of the vehicle-infused con-
trol group was almost devoid of pErk1/2-positive cells.
Furthermore, and even more pronounced, more pErk1/2-
immunoreactive cells were present in the central part of the lat-
eral division of the central nucleus. The pErk1/2-positive cells
represent the multipolar principal cells of the amygdalar subnu-
clei. Increased density of pErk1/2 cells was also found in the me-
dial amygdalar nucleus, whereas the other subnuclei of the
amygdala revealed pErk1/2-stained cells only occasionally. The
Figure 1. Ipsilateral, but not contralateral, lesions of the BLA block inhibitory avoidance retention enhancement induced by
posttraining intra-mPFC infusions of a GR agonist. Step-through latencies (mean  SEM) in seconds on the 48 h inhibitory
avoidance retention test of rats with unilateral sham- or NMDA-induced lesions of the BLA given the GR agonist RU 28362 (3 or 10
ng in 0.5 l) into the left mPFC immediately after training. A, Ipsilateral BLA lesion. B, Contralateral BLA lesion. ✷p 0.05;
✷✷p 0.01 compared with the corresponding vehicle group; p 0.05 compared with the corresponding sham lesion–RU
28362 group (n 8–14per group). C, Injection needle tips in themPFC of 20 randomly selected sham-lesioned (black circles) and
20 BLA-lesioned rats (black diamonds) included in the experiment. D, Smallest (black area) and largest (gray area) ipsilateral and
contralateral BLA lesions from rats used in the analysis. Adapted from Paxinos andWatson (2005).
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intercalated mass was characterized by moderate levels of pErk1/
2-positive neurons (data not shown). Other brain regions did not
show such an increase in pErk1/2 immunoreactivity, illustrating
the brain region-specific nature of the GR agonist-induced
pErk1/2 changes.
AMEK inhibitor infused into the BLA blocks retention
enhancement induced by posttraining infusion of a GR
agonist into the mPFC
If the increased pErk1/2 expression in the BLA plays a role in
mediating the memory-enhancing effect of RU 28362 infused
into the mPFC, then a blockade of pErk1/2 activity in the BLA
should prevent the retention enhancement induced by immedi-
ate posttraining intra-mPFC administration of the GR agonist.
To investigate this issue, rats were given unilateral infusions of
the specific MEK inhibitor PD98059 (20 ng in 0.2 l) or vehicle
into the left BLA together with the GR agonist RU 28362 (3 or 10
ng) or vehicle into the ipsilateral mPFC immediately after inhib-
itory avoidance training. Two-way ANOVA for entrance laten-
cies on the training trial, before footshock and drug treatment,
did not show significant differences between groups ( p  0.08
for all comparisons) (data not shown). As shown in Figure 3A,
two-way ANOVA for retention latencies revealed a significant
RU 28362 effect (F(2,62) 3.53; p 0.05), a significant PD98059
effect (F(1,62) 7.62; p 0.01), as well as a significant interaction
between both factors (F(2,62)  5.07; p  0.01). Posttraining in-
fusions of the higher dose of RU 28362 (10 ng) into the mPFC
enhanced retention of rats given vehicle into the BLA, compared
with the retention of corresponding vehicle-treated rats ( p 
0.01). Infusion of a low dose of the MEK inhibitor into the ipsi-
lateral BLA did not impair retention latencies when adminis-
tered alone ( p  0.34) but blocked the retention-enhancing
effect of RU 28362 administered into the mPFC. Retention
latencies of RU 28362-treated rats given PD98059 into the
BLA were significantly shorter than
those of RU 28362-treated rats given ve-
hicle into the BLA (10 ng, p  0.01).
Figure 3B shows the location of infu-
sion needle tips in the left mPFC and BLA
of 30 randomly selected animals.
GR agonist infusions into the BLA after
inhibitory avoidance training increase
pErk1/2 levels in the mPFC
In the first experiments above, we found
that immediate posttraining manipula-
tion of GR activity in the mPFC with the
receptor agonist RU 28362 enhanced 48 h
inhibitory avoidance retention perfor-
mance via an influence involving the BLA.
However, as the BLA is also known to
project to the mPFC, it is possible that the
well known memory enhancement in-
duced by GR agonist infusions into the
BLA may also depend on concurrent
changes induced in the mPFC. To exam-
ine whether posttraining infusions of RU
28362 into the BLA increase pErk1/2 ac-
tivity in the mPFC, RU 28362 (1 or 3 ng)
or vehicle was infused into the left BLA
immediately after inhibitory avoidance
training and rats were killed 15 min later
for quantification of pErk1/2 levels in the
ipsilateral and contralateral mPFC. Figure 4A illustrates the ratio
of pErk1/2 protein levels, normalized to total MAP kinase, in the
mPFC across the two hemispheres. One-way ANOVA revealed a
significant difference across groups (F(2,19) 6.04; p 0.01). For
rats given either dose of RU 28362 into the left BLA, the ratio of
pErk1/2 protein levels in the mPFC between the ipsilateral and
contralateral side was significantly greater than that in rats ad-
ministered vehicle (both doses, p 0.01). In contrast, in rats that
were not trained on the inhibitory avoidance task, pErk1/2 levels
in themPFC did not increase after infusions of RU 28362 into the
BLA (F(2,12) 0.18; p 0.84). Figure 4B shows a representative
example of an immunoblot illustrating pErk1/2 and total MAP
kinase levels in the ipsilateral and contralateral mPFC of the dif-
ferent experimental groups.
To qualitatively confirm the Western blot data, we deter-
mined immunoreactivity levels of pErk1/2 in the mPFC 15 min
after a unilateral infusion of RU 28362 (3 ng) or vehicle into the
left BLA. As is shown in Figure 4C, RU 28362 treatment in the
BLA increased the density of pErk1/2-positive neurons in both
the prelimbic and infralimbic regions of the ipsilateral mPFC
compared with rats given a vehicle infusion, although pErk1/2-
immunopositive neurons were also present in this group. The
increased density of pErk1/2 cells was predominantly found in
layers 2 and 3, in cells with a long apical dendrite. These cellsmost
likely represent pyramidal cells.
AMEK inhibitor infused into the mPFC blocks retention
enhancement induced by posttraining infusion of a GR
agonist into the BLA
To determine whether this increased pErk1/2 activity in the
mPFC is involved in mediating the memory-enhancing effect of
GR agonist infusions into the BLA, we examined whether a MEK
inhibitor infused into the mPFC blocked this retention enhance-
ment. Two-way ANOVA for entrance latencies on the training
A C
B
Figure 2. GR agonist RU 28362 (3 or 10 ng in 0.5 l) infusions into the mPFC after inhibitory avoidance training increase
pErk1/2 levels in the BLA. A, Mean ratio (SEM) of pErk1/2 in the BLA ipsilateral to mPFC infusions versus pErk1/2
measured in the contralateral BLA is significantly greater in rats administered RU 28362 than the ratio of the comparison across
two hemispheres of vehicle-treated rats. ✷p 0.05; ✷✷p 0.01 (n 6–11 per group). No significant differences were
observed across hemispheres in rats that were not trained on the inhibitory avoidance task (n 5–6 per group). B, Density of
pErk1/2 bands was normalized to density of total MAP kinase bands on the same blot. Left band is ipsilateral (i) to mPFC infusion,
and right is contralateral (c). C, Immunohistochemical demonstration of location of pErk1/2 within the amygdala. Positive cells
were present in the BLA as well as in the central part of the lateral division of the central nucleus (CEA).
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trial, before footshock and drug treatment, did not show signifi-
cant differences between groups ( p  0.13 for all comparisons)
(data not shown). Figure 5 shows 48 h inhibitory avoidance re-
tention latencies of rats given immediate posttraining infusions
of the MEK inhibitor PD98059 (50 ng) or vehicle into the left
mPFC together with the GR agonist RU 28362 (1 or 3 ng) or
vehicle into the ipsilateral BLA. Two-way ANOVA for retention
latencies revealed a significant RU 28362 effect (F(2,63)  3.75;
p 0.05), a significant PD98059 effect (F(1,63) 8.37; p 0.01),
as well as a significant interaction between both factors (F(2,63)
4.67; p  0.05). Posttraining infusion of the higher dose of RU
28362 (3 ng) into the BLA enhanced retention of rats given vehi-
cle into themPFC, comparedwith the retention of corresponding
vehicle-treated rats ( p  0.01). Infusion of PD98059 into the
ipsilateral mPFC did not impair retention latencies when admin-
istered alone ( p  0.95) but blocked the retention-enhancing
effects of RU 28362 administered into the BLA. Furthermore,
retention latencies of RU 28362-treated rats given PD98059 into
the mPFC were significantly shorter than retention latencies of
RU28362-treated rats given vehicle into the BLA (3 ng, p 0.01).
GR agonist infusions into the mPFC or BLA enhance memory
for similar components of inhibitory avoidance training
If, as suggested by the findings described above, the mPFC and
BLA function as a circuit in enhancing GR agonist effects on
memory consolidation, then it may be expected that the BLA and
mPFC enhance memory of the same components of information
acquired during inhibitory avoidance training. In inhibitory
avoidance, rats learn both that they received a footshock as well as
where they received the footshock. However, with traditional
one-trial inhibitory avoidance training, it is not possible to deter-
mine whether the GR agonist infusions into the BLA or mPFC
specifically enhanced memory of the context exposure, the foot-
shock experience, or of both components of training. Recently, a
modified, two-phase inhibitory avoidanceprocedurewas developed
to separate the learning about the context
from the learning about the footshock. On
the first day, animals freely explore the in-
hibitory avoidance apparatus to learn
about the context and 24 h later are very
briefly placed back into the shock com-
partment to receive footshock (Malin and
McGaugh, 2006). In the present experi-
ment, rats were trained on the two-phase
inhibitory avoidance procedure and given
bilateral infusions of the GR agonist RU
28362 into either the BLA (1 or 3 ng in 0.2
l) or mPFC (3 or 10 ng in 0.5l) after the
context training or footshock training.
Figure 6A shows 48 h retention laten-
cies of animals given GR agonist infusions
into the BLA immediately after context or
shock training of inhibitory avoidance.
One-way ANOVAs for retention latencies
revealed significant group effects of rats
given intra-BLA infusions of RU 28362 im-
mediatelyafter eithercontext (F(2,32)6.55;
p  0.005) or shock training (F(2,35) 
5.52; p 0.01). Retention latencies of rats
given intra-BLA infusions of the 1 or 3 ng
dose of RU 28362 immediately after either
context or shock training were signifi-
cantly longer than those of their respective
B
A
Figure 3. A MEK inhibitor infused into the BLA blocks inhibitory avoidance retention en-
hancement induced by posttraining GR agonist infusions into themPFC.A, Step-through laten-
cies (mean SEM) in seconds on the 48 h inhibitory avoidance retention test of rats given
immediate posttraining infusions of the GR agonist RU 28362 (3 or 10 ng in 0.5l) into the left
mPFC either alone or together with the MEK inhibitor PD98059 (20 ng in 0.2 l) into the
ipsilateral BLA. ✷✷p 0.01 compared with the corresponding vehicle group; p 0.01
comparedwith the corresponding saline–RU28362 group (n 10–13per group).B, Injection
needle tips in the left mPFC and BLA of 30 randomly selected rats included in the experiment.
A C
B
Figure 4. Infusions of the GR agonist RU 28362 (1 or 3 ng in 0.2l) into the BLA after inhibitory avoidance training increase
pErk1/2 levels in the mPFC. A, Mean ratio (SEM) of pErk1/2 in the mPFC ipsilateral to BLA infusions versus pErk1/2 measured in the
contralateralmPFCissignificantlygreaterinratsgivenRU28362thantheratioofthecomparisonacrosstwohemispheresofvehicle-treated
rats. ✷✷p0.01 (n7–8pergroup).No significantdifferenceswereobservedacrosshemispheres in rats thatwerenot trainedon the
inhibitory avoidance task (n 4–6per group).B, Density of pErk1/2 bandswas normalized to density of totalMAP kinase bands on the
same blot. The left band is ipsilateral (i) to intra-BLA infusion, and right is contralateral (c). C, Immunohistochemical demonstration of
location of pErk1/2within themPFC. Positive cells were present in neurons in both the prelimbic and infralimbic regions of the ipsilateral
mPFC, particularly in pyramidal cells of layers 2 and 3. Note pErk1/2 immunoreactivity in apical dendrites in this area.
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vehicle controls (for both context and shock: 1 ng, p 0.05; 3 ng,
p 0.01). Retention latencies of animals given intra-mPFC infu-
sions of RU 28362 or vehicle immediately after context or shock
training of inhibitory avoidance are shown in Figure 6B. Very
similar to the effects of BLA infusions, one-way ANOVAs revealed
significant differences in retention latencies of animals given the
GR agonist after either context (F(2,49) 4.02; p 0.05) or shock
training (F(2,40)  3.55; p  0.05). Retention latencies of rats
given either the 3 or 10 ng dose of RU 28362 immediately after
either context or shock training were significantly longer than
those of their respective vehicle controls (after context: 3 ng, p
0.05; 10 ng, p 0.01; after shock: both doses, p 0.05). Impor-
tantly, RU 28362 administered into the BLA (3 ng) or the mPFC
(10 ng) after either context or shock training to animals that did
not receive the other component of training did not enhance 48 h
retention latencies, indicating that the expression of the en-
hanced memory depends on learning about both context and
footshock (Table 1).
Discussion
These findings provide evidence that glucocorticoid effects on the
consolidation of memory for inhibitory avoidance training de-
pend on functional interactions between the BLA andmPFC. The
memory-enhancing effect of an immediate posttraining infusion
of the GR agonist RU 28362 administered into the mPFC de-
pends on an increased phosphorylation of Erk1/2 in the BLA,
and, similarly, the memory enhancement induced by intra-BLA
administration of RU 28362 requires elevated pErk1/2 levels in
themPFC.Moreover, the finding that theGRagonist infused into
either the BLA or the mPFC enhances the consolidation of
memory of both the contextual and aversively motivated as-
pects of information acquired during inhibitory avoidance
training strongly suggests that these two brain regions func-
tion as a bidirectional circuit in emotional regulation of mem-
ory consolidation.
Considerable evidence from electrophysiological studies indi-
cates that the mPFC and BLA interact (Timms, 1977; Pe´rez-
Jaranay and Vives, 1991; Rosenkranz and Grace, 2002; Maroun
and Richter-Levin, 2003; Likhtik et al., 2005) and that mPFC–
BLA interactions regulate performance on affectively motivated
tasks (Schoenbaum et al., 1998; Bechara et al., 1999). For exam-
ple, several studies implicatemPFC–BLA interactions in control-
ling the expression and extinction of conditioned fear (Garcia et
al., 1999; Milad and Quirk, 2002). Moreover, we previously re-
ported that lesions of the BLA block working memory impair-
ment induced by intra-mPFC infusions of a GR agonist
(Roozendaal et al., 2004). The present experiments investigated
whether the mPFC and BLA interact in regulating the consolida-
tion of memory of emotionally arousing training experiences.
The first experiment determined that a lesion of the BLA made
ipsilaterally to the mPFC infusion site blocked the GR agonist-
induced memory enhancement, indicating that an intact and
functional BLA is required for mediating the modulatory in-
fluences of intra-mPFC glucocorticoid administration on
memory consolidation. As a contralateral BLA lesion did not
block the GR agonist-induced memory enhancement, evidence
indicates that the interaction is mediated directly through neural
pathways connecting these two brain regions (Krettek and Price,
1977; Russchen, 1982) rather than by an effect of GR manipu-
lation on hypothalamic–pituitary–adrenocortical axis activity.
These findings are very similar to those of previous studies indi-
cating that a disruption of BLA activity blocks memory enhance-
ment induced by the administration of a glucocorticoid or other
memory-enhancing compound into the hippocampus, dorsal
striatum, entorhinal cortex, insular cortex, or anterior cingulate
cortex (Roozendaal and McGaugh, 1997a; Roesler et al., 2002;
Miranda and McGaugh, 2004; Malin et al., 2007) and further
support the view that the BLA regulates memory consolidation
via interactions with many brain regions (McGaugh, 2002).
Whereas previous findings suggest that the BLA regulates
neuroplasticity andmemory consolidation primarily through ef-
ferent projections from the BLA to these other brain regions
(McGaugh, 2002), the present results indicate that interactions
between the BLA and mPFC in modulating memory consolida-
tion are bidirectional and, thus, that BLA activity does not simply
regulate information storage processes in themPFC. Our finding
that the GR agonist infused unilaterally into the mPFC immedi-
ately after inhibitory avoidance training elevated pErk1/2 levels in
the ipsilateral BLA shows that a manipulation of GR activity in
the mPFC modulates BLA activity. The observation that the GR
Figure 5. A MEK inhibitor infused into the mPFC blocks inhibitory avoidance retention en-
hancement induced by posttraining GR agonist infusions into the BLA. Step-through latencies
(mean SEM) in seconds on the 48 h inhibitory avoidance retention test of rats given imme-
diate posttraining infusions of the GR agonist RU 28362 (1 or 3 ng in 0.2l) into the left BLA
either alone or together with the MEK inhibitor PD98059 (50 ng in 0.5l) into the ipsilateral
mPFC. ✷✷p0.01 comparedwith the corresponding vehicle group; p0.01 compared
with the corresponding vehicle–RU 28362 group (n 10–13 per group).
A B
Figure 6. GR agonist infusions into the BLA or mPFC enhance memory for similar compo-
nents of inhibitory avoidance training. Step-through latencies (mean SEM) in seconds on the
48 h retention test of rats given bilateral infusions of the GR agonist RU 28362 into the BLA or
mPFC immediately after either context or shock training on the two-phase modified inhibitory
avoidance task.A, Posttraining infusions of RU28362 (1or 3ng in0.2l) into theBLAenhanced
inhibitory avoidance retention latencieswhenadministeredafter either the context exposureor
the shock experience.B, Posttraining infusions of theGR agonist RU 28362 (3 or 10 ng in 0.5l)
into the mPFC enhanced inhibitory avoidance retention latencies when administered after
either the context exposure or the shock experience. ✷p 0.05; ✷✷p 0.01 comparedwith
the corresponding vehicle group (n 10–18 per group).
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agonist also increased pErk1/2 levels in the central part of the
lateral division of the central amygdala, intercalated mass, and to
a lesser extent the medial amygdala is consistent with evidence
that the mPFC has projection neurons to these other regions
(Cassell andWright, 1986).Wemeasured pErk1/2 levels to assess
BLA activity because Erk is a rapidly activated protein that has
been implicated in neuroplasticity and memory consolidation
(Atkins et al., 1998; Schafe et al., 2000). Moreover, and most
importantly, as the specific MEK inhibitor PD98059 infused se-
lectively into the BLA blocked this memory enhancement, these
findings suggest that this increased phosphorylation of Erk1/2 in
the BLA is essential in mediating the memory-modulatory effect
of intra-mPFC GR agonist administration. As some evidence
suggests that the medial amygdala, but not the central amygdala,
is also involved in regulating stress hormone effects on memory
consolidation (Roozendaal and McGaugh, 1996), it is possible
that mPFC influences on pErk1/2 activity within the medial
amygdala normally contribute to the enhanced retention initi-
ated by GR agonist infusion into the mPFC. Highly comparable
with the effects of GR agonist infusions into the mPFC, RU
28362 administration into the BLA after inhibitory avoidance
training induced a rapid increase in pErk1/2 levels in both the
prelimbic and infralimbic regions of the mPFC. Furthermore,
an immediate posttraining infusion of a MEK inhibitor into
the mPFC blocked the memory enhancement induced by
intra-BLA administration of the GR agonist. Thus, the find-
ings indicate that a GR agonist infusion into the mPFC influ-
ences BLA activity, whereas a GR agonist infusion into the BLA
alters mPFC activity. Interference with this process at either
site prevents the enhancing effect of glucocorticoid adminis-
tration onmemory consolidation, likely by disturbing the pro-
cessing of information storage occurring in distal brain
regions (McGaugh, 2002; Roozendaal, 2002). To date, it is not
known whether glucocorticoid modulation of memories in
these distal brain regions also depends on increased pErk1/2
levels in the mPFC and/or BLA.
Interestingly, several findings indicate that glucocorticoid ef-
fects on memory consolidation depend on pErk1/2-MAP kinase
activation. For example, Revest et al. (2005) reported that stress
or corticosterone induced a slow-onset (after 2 h) increase in the
expression and enzymatic activity of the MAP kinase pathway in
the hippocampus. Blockade of this effect with intrahippocampal
infusions of a MEK inhibitor prevented glucocorticoid effects on
fear memory consolidation. Our data appear to differ in two
important ways: First, our findings clearly demonstrate that GR
agonist administration into either the mPFC or BLA induces
pErk1/2 activation in the other brain site. Second, our data indi-
cate elevated pErk1/2 levels in the mPFC or BLA within 15 min
after GR agonist administration. Such a time frame strongly sug-
gests the involvement of a nongenomic glucocorticoid action,
possibly through an activation of membrane-associated recep-
tors (Dallman, 2005; Johnson et al., 2005). Such findings are
consistent with evidence of rapid interactions of glucocorticoids
or GR agonist with arousal-induced noradrenergic and endocan-
nabinoid mechanisms in influencing neuroplasticity and mem-
ory consolidation (Quirarte et al., 1997; Roozendaal et al., 2006;
Pu et al., 2007; Campolongo et al., 2009). Also, the findings that
the GR agonist did not alter pErk1/2 levels when infused into
either the mPFC or BLA of nontrained control animals support
the view that glucocorticoids affect BLA–mPFC circuitry and en-
hance memory consolidation only under conditions of emo-
tional arousal.
Additional support for a necessary interaction between the
BLA and mPFC in regulating glucocorticoid effects on memory
consolidation in efferent brain regions was provided by our find-
ing that both brain regions played a role in GR agonist effects on
the consolidation of memory of contextual and aversively moti-
vated aspects of inhibitory avoidance training. As noted above,
BLA activation is known to enhance the consolidation ofmemory
of many different training experiences via interactions with dif-
ferent brain regions (McGaugh, 2002). The present demonstra-
tion that the GR agonist administered into the mPFC, like
infusions into the BLA, enhanced retention when administered
after either the context training or footshock experience indicate
that both brain regions share a functional commonality and
strongly support the view that both brain regions cooperate in
regulating memory consolidation. In contrast, previous experi-
ments investigating the effect of drug administration into the
hippocampus, anterior cingulate cortex, or dorsal striatum after
training on the two-phase inhibitory avoidance task indicated
that those brain regions are dedicated to the selectivemodulation
of memory of specific components of the training experience
(Malin and McGaugh, 2006; Medina et al., 2007; Roozendaal et
al., 2008). These findings not only substantiate the unique roles of
the BLA and mPFC, and their interaction, in emotional regula-
tion of memory consolidation of many different types of training
experiences (Tronel and Sara, 2003; Xiang and Brown, 2004;
Touzani et al., 2007; McDonald et al., 2008), but also strongly
suggest that drug infusions into these other brain regions do not
simply enhancememory consolidation by activating the BLA and
mPFC. Rather, these findings are consistent with our view that
the BLA–mPFC circuit regulates memory consolidation in these
other, distal brain regions. Several studies indicate that such in-
teractions between the mPFC and BLA may be essential for an
adaptive regulation of affect andmemory (Amat et al., 2005) and
to exert a cognitive and emotional control to downregulate lim-
bic circuitry (Burgos-Robles et al., 2007; Mueller et al., 2008).
In summary, we demonstrate a crucial role for bidirectional
interactions between the BLA and mPFC in regulating glucocor-
ticoid effects on memory consolidation. Abnormalities in the
BLA andmPFC are consistently noted in affective disorders such
as post-traumatic stress disorder and major depressive illness
(Bremner et al., 1999; Johnstone et al., 2007). The identification
of the nature and functional dynamics of this BLA–mPFC circuit
that modulate emotional arousal effects on memory consolida-
tion may lead to an improved understanding of how this system
may be involved in the aberrant cognitive and emotional re-
sponses observed in affective disorders.
Table 1. Effect of RU 28362 after context or shock exposure alone
Context exposure alone Footshock exposure alone
Vehicle RU 28362 Vehicle RU 28362
BLA 10.1 3.0 (7) 7.3 0.7 (7) p 0.38 8.9 2.9 (7) 14.7 7.0 (7) p 0.46
mPFC 13.7 1.7 (7) 13.8 3.5 (7) p 0.97 13.2 6.1 (5) 13.9 4.2 (7) p 0.92
Shown are retention latencies (mean SEM) in seconds. The numbers of animals per group are indicated in parentheses. The dose of RU 28362 administered into the BLA was 3 ng in 0.2l and that into the mPFC was 10 ng in 0.5l.
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